PHARMA: Bristol-Myers to Stop U.S. Sale of Serzone

BMS is pulling its poorly selling anti-depressant Serzone off the market. BMS blames poor sales for the move, but the drug has been blamed for liver problems and the folks at Public Citizen have been suing to force a full recall (rather than just stopping sales) and the cessation of sales of generics.

Overall this will have modest effect on BMS attempts at revival–the way the company deals with the patent expiry of Pravachol will be much more important. As mentioned last week in THCB, Forbes believes they’ll do OK.

Categories: Uncategorized

Tagged as: ,